IBO Valuation
Impact Biomedical Inc
$
0.650
- Overview
- Forecast
- Valuation
- Earnings
IBO Relative Valuation
IBO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, IBO is overvalued; if below, it's undervalued.
Historical Valuation
Impact Biomedical Inc (IBO) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 0.00. The fair price of Impact Biomedical Inc (IBO) is between to according to relative valuation methord.
Relative Value
Fair Zone
-
Current Price：0.65
Fair
0.00
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
Impact Biomedical Inc. (IBO) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.
0.00
EV/EBIT
Impact Biomedical Inc. (IBO) has a current EV/EBIT of 0.00. The 5-year average EV/EBIT is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBIT of 0.00 falls within the Strongly Undervalued range.
0.00
PS
Impact Biomedical Inc. (IBO) has a current PS of 0.00. The 5-year average PS is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward PS of 0.00 falls within the Strongly Undervalued range.
0.00
P/OCF
Impact Biomedical Inc. (IBO) has a current P/OCF of 0.00. The 5-year average P/OCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/OCF of 0.00 falls within the Strongly Undervalued range.
0.00
P/FCF
Impact Biomedical Inc. (IBO) has a current P/FCF of 0.00. The 5-year average P/FCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/FCF of 0.00 falls within the Strongly Undervalued range.
Impact Biomedical Inc (IBO) has a current Price-to-Book (P/B) ratio of -0.70. Compared to its 3-year average P/B ratio of 1.00 , the current P/B ratio is approximately -170.12% higher. Relative to its 5-year average P/B ratio of 1.00, the current P/B ratio is about -170.12% higher. Impact Biomedical Inc (IBO) has a Forward Free Cash Flow (FCF) yield of approximately -62.69%. Compared to its 3-year average FCF yield of -36.39%, the current FCF yield is approximately 72.26% lower. Relative to its 5-year average FCF yield of -36.39% , the current FCF yield is about 72.26% lower.
-0.70
P/B
Median3y
1.00
Median5y
1.00
-62.69
FCF Yield
Median3y
-36.39
Median5y
-36.39
Competitors Valuation Multiple
The average P/S ratio for IBO's competitors is 0.18, providing a benchmark for relative valuation. Impact Biomedical Inc Corp (IBO) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of IBO increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of IBO in the past 1 year is driven by Unknown.
People Also Watch
JFU
9F Inc
2.444
USD
+1.62%
MCVT
Mill City Ventures III Ltd
6.400
USD
-5.24%
SLNH
Soluna Holdings Inc
0.500
USD
+2.04%
NCL
Northann Corp
0.155
USD
-1.90%
LFWD
Lifeward Ltd
0.571
USD
-7.61%
GIGM
GigaMedia Ltd
1.540
USD
+0.33%
SOHO
Sotherly Hotels Inc
0.820
USD
+11.26%
MIGI
Mawson Infrastructure Group Inc
0.329
USD
-16.71%
ASPS
Altisource Portfolio Solutions SA
11.290
USD
-0.35%
FAQ
Is Impact Biomedical Inc (IBO) currently overvalued or undervalued?
Impact Biomedical Inc (IBO) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 0.00. The fair price of Impact Biomedical Inc (IBO) is between to according to relative valuation methord.
What is Impact Biomedical Inc (IBO) fair value?
How does IBO's valuation metrics compare to the industry average?
What is the current P/B ratio for Impact Biomedical Inc (IBO) as of Sep 03 2025?
What is the current FCF Yield for Impact Biomedical Inc (IBO) as of Sep 03 2025?
What is the current Forward P/E ratio for Impact Biomedical Inc (IBO) as of Sep 03 2025?